Safety and Tolerability of Z-100 in Patients With Early HIV Infection
Phase 1
Terminated
- Conditions
- HIV Infections
- Registration Number
- NCT00016692
- Lead Sponsor
- Zeria Pharmaceutical
- Brief Summary
The purpose of the study is to see if Z-100 (an investigational drug) treatment is safe in HIV patients who have never received treatment for their HIV, who have not been taking highly active antiretroviral therapy (HAART) for at least 8 weeks, or who have been stable on their current first or second HAART regimen for at least 12 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
UCSF - San Francisco Gen Hosp
🇺🇸San Francisco, California, United States
Northwestern Univ Med School
🇺🇸Chicago, Illinois, United States
Univ TX Med Branch
🇺🇸Galveston, Texas, United States